Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Pharmacology and Experimental Therapeutics
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Journal of Pharmacology and Experimental Therapeutics

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit jpet on Facebook
  • Follow jpet on Twitter
  • Follow jpet on LinkedIn
Research ArticleNeuropharmacology

Novel N-Phenyl–Substituted Thiazolidinediones Protect Neural Cells against Glutamate- and tBid-Induced Toxicity

Sina Oppermann, Florian C. Schrader, Katharina Elsässer, Amalia M. Dolga, Anna Lena Kraus, Nunzianna Doti, Christof Wegscheid-Gerlach, Martin Schlitzer and Carsten Culmsee
Journal of Pharmacology and Experimental Therapeutics August 2014, 350 (2) 273-289; DOI: https://doi.org/10.1124/jpet.114.213777
Sina Oppermann
Institute for Pharmacology and Clinical Pharmacy, Faculty of Pharmacy (S.O., K.E., A.M.D., C.C.) and Institute for Pharmaceutical Chemistry, Faculty of Pharmacy, Philipps University of Marburg, Marburg, Germany (F.C.S., A.L.K., C.W.-G., M.S.); and Institute of Biostructures and Bioimaging, Naples, Italy (N.D.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Florian C. Schrader
Institute for Pharmacology and Clinical Pharmacy, Faculty of Pharmacy (S.O., K.E., A.M.D., C.C.) and Institute for Pharmaceutical Chemistry, Faculty of Pharmacy, Philipps University of Marburg, Marburg, Germany (F.C.S., A.L.K., C.W.-G., M.S.); and Institute of Biostructures and Bioimaging, Naples, Italy (N.D.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Katharina Elsässer
Institute for Pharmacology and Clinical Pharmacy, Faculty of Pharmacy (S.O., K.E., A.M.D., C.C.) and Institute for Pharmaceutical Chemistry, Faculty of Pharmacy, Philipps University of Marburg, Marburg, Germany (F.C.S., A.L.K., C.W.-G., M.S.); and Institute of Biostructures and Bioimaging, Naples, Italy (N.D.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Amalia M. Dolga
Institute for Pharmacology and Clinical Pharmacy, Faculty of Pharmacy (S.O., K.E., A.M.D., C.C.) and Institute for Pharmaceutical Chemistry, Faculty of Pharmacy, Philipps University of Marburg, Marburg, Germany (F.C.S., A.L.K., C.W.-G., M.S.); and Institute of Biostructures and Bioimaging, Naples, Italy (N.D.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anna Lena Kraus
Institute for Pharmacology and Clinical Pharmacy, Faculty of Pharmacy (S.O., K.E., A.M.D., C.C.) and Institute for Pharmaceutical Chemistry, Faculty of Pharmacy, Philipps University of Marburg, Marburg, Germany (F.C.S., A.L.K., C.W.-G., M.S.); and Institute of Biostructures and Bioimaging, Naples, Italy (N.D.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nunzianna Doti
Institute for Pharmacology and Clinical Pharmacy, Faculty of Pharmacy (S.O., K.E., A.M.D., C.C.) and Institute for Pharmaceutical Chemistry, Faculty of Pharmacy, Philipps University of Marburg, Marburg, Germany (F.C.S., A.L.K., C.W.-G., M.S.); and Institute of Biostructures and Bioimaging, Naples, Italy (N.D.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christof Wegscheid-Gerlach
Institute for Pharmacology and Clinical Pharmacy, Faculty of Pharmacy (S.O., K.E., A.M.D., C.C.) and Institute for Pharmaceutical Chemistry, Faculty of Pharmacy, Philipps University of Marburg, Marburg, Germany (F.C.S., A.L.K., C.W.-G., M.S.); and Institute of Biostructures and Bioimaging, Naples, Italy (N.D.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Martin Schlitzer
Institute for Pharmacology and Clinical Pharmacy, Faculty of Pharmacy (S.O., K.E., A.M.D., C.C.) and Institute for Pharmaceutical Chemistry, Faculty of Pharmacy, Philipps University of Marburg, Marburg, Germany (F.C.S., A.L.K., C.W.-G., M.S.); and Institute of Biostructures and Bioimaging, Naples, Italy (N.D.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Carsten Culmsee
Institute for Pharmacology and Clinical Pharmacy, Faculty of Pharmacy (S.O., K.E., A.M.D., C.C.) and Institute for Pharmaceutical Chemistry, Faculty of Pharmacy, Philipps University of Marburg, Marburg, Germany (F.C.S., A.L.K., C.W.-G., M.S.); and Institute of Biostructures and Bioimaging, Naples, Italy (N.D.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF + SI
  • PDF
Loading

Abstract

Mitochondrial demise is a key feature of progressive neuronal death contributing to acute and chronic neurological disorders. Recent studies identified a pivotal role for the BH3-only protein B-cell lymphoma-2 interacting domain death antagonist (Bid) for such mitochondrial damage and delayed neuronal death after oxygen-glucose deprivation, glutamate-induced excitotoxicity, or oxidative stress in vitro and after cerebral ischemia in vivo. Therefore, we developed new N-phenyl–substituted thiazolidine-2,4-dione derivatives as potent inhibitors of Bid-dependent neurotoxicity. The new compounds 6, 7, and 16 were identified as highly protective by extensive screening in a model of glutamate toxicity in immortalized mouse hippocampal neurons (HT-22 cells). These compounds significantly prevent truncated Bid–induced toxicity in the neuronal cell line, providing strong evidence that inhibition of Bid was the underlying mechanism of the observed protective effects. Furthermore, Bid-dependent hallmarks of mitochondrial dysfunction, such as loss of mitochondrial membrane potential, ATP depletion, as well as impairments in mitochondrial respiration, are significantly prevented by compounds 6, 7, and 16. Therefore, the present study identifies a class of N-phenyl thiazolidinediones as novel Bid-inhibiting neuroprotective agents that provide promising therapeutic perspectives for neurodegenerative diseases, in which Bid-mediated mitochondrial damage and associated intrinsic death pathways contribute to the underlying progressive loss of neurons.

Footnotes

    • Received February 5, 2014.
    • Accepted May 16, 2014.
  • This work was supported by the research funds of the University of Marburg.

  • dx.doi.org/10.1124/jpet.114.213777.

  • ↵Embedded ImageThis article has supplemental material available at jpet.aspetjournals.org.

  • Copyright © 2014 by The American Society for Pharmacology and Experimental Therapeutics
View Full Text

JPET articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Journal of Pharmacology and Experimental Therapeutics: 350 (2)
Journal of Pharmacology and Experimental Therapeutics
Vol. 350, Issue 2
1 Aug 2014
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Editorial Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Journal of Pharmacology and Experimental Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Novel N-Phenyl–Substituted Thiazolidinediones Protect Neural Cells against Glutamate- and tBid-Induced Toxicity
(Your Name) has forwarded a page to you from Journal of Pharmacology and Experimental Therapeutics
(Your Name) thought you would be interested in this article in Journal of Pharmacology and Experimental Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleNeuropharmacology

Thiazolidinediones as Novel Neuroprotectants

Sina Oppermann, Florian C. Schrader, Katharina Elsässer, Amalia M. Dolga, Anna Lena Kraus, Nunzianna Doti, Christof Wegscheid-Gerlach, Martin Schlitzer and Carsten Culmsee
Journal of Pharmacology and Experimental Therapeutics August 1, 2014, 350 (2) 273-289; DOI: https://doi.org/10.1124/jpet.114.213777

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleNeuropharmacology

Thiazolidinediones as Novel Neuroprotectants

Sina Oppermann, Florian C. Schrader, Katharina Elsässer, Amalia M. Dolga, Anna Lena Kraus, Nunzianna Doti, Christof Wegscheid-Gerlach, Martin Schlitzer and Carsten Culmsee
Journal of Pharmacology and Experimental Therapeutics August 1, 2014, 350 (2) 273-289; DOI: https://doi.org/10.1124/jpet.114.213777
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Authorship Contributions
    • Footnotes
    • Abbreviations
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF + SI
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Glycine receptor modulation using monoclonal antibodies
  • Iclepertin (BI 425809) in Schizophrenia-Related Models
  • D1 Agonist Versus Methylphenidate on PFC Working Memory
Show more Neuropharmacology

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About JPET
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0103 (Online)

Copyright © 2022 by the American Society for Pharmacology and Experimental Therapeutics